CELL INTELLIGENCE · 肿瘤细胞治疗研究

iPSCs 在 BCMA 靶向治疗多发性骨髓瘤中的现状与前景

The Current Landscape and Prospects of iPSCs in BCMA-targeted Therapy for Multiple Myeloma.

障碍与蓝图：胃肠道肿瘤中 CAR-T 细胞治疗的下一代工程策略

Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.

癌症之外的 CAR 工程化细胞治疗：重编程纤维化和免疫介导炎症

CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.

推进胶质母细胞瘤 CAR-T 细胞疗法前沿：从临床障碍到突破性策略的现状探索

Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough s

异基因 iPSC 来源 γδT 细胞对患者来源组织显示抗肿瘤疗效

Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues.

一种用于通用药物递送和免疫治疗的可再生、可编程的 iPSC 来源血小板平台

A regenerative and programmable iPSC-derived platelet platform for universal drug delivery and immunotherapy.

诱导多能干细胞来源 NK 细胞作为肿瘤免疫治疗的现货型平台：机遇、挑战与临床转化

Induced Pluripotent Stem Cell-Derived NK Cells as an Off-the-Shelf Platform for Cancer Immunotherapy: Opportunities, Challenges, and Clinical Translat

源自诱导多能干细胞的 CAR 工程化中性粒细胞：细胞免疫治疗的新前沿

CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.

IL-15 与 IL-21 协同作用提高 iPSC 来源的细胞毒性 T 细胞在实体瘤中的抗肿瘤疗效

IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors.

经巨噬细胞靶向 EGFR(VIII) 突变胶质母细胞瘤细胞的新型嵌合抗原受体（CAR）策略

A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFR(VIII)-mutated glioblastoma cells via macrophages.

本工作所描述的模型适合用于向 iPSC 来源巨噬细胞的转化，以在表达突变变体 EGFR VIII 的实体瘤中产生未来可临床应用的细胞治疗方法。